Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp Has $15.57 Million Stake in Valeant Pharmaceuticals (VRX)

Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp increased its holdings in shares of Valeant Pharmaceuticals (NYSE:VRX) (TSE:VRX) by 1.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 508,900 shares of the specialty pharmaceutical company’s stock after buying an additional 7,500 shares during the quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp owned 0.15% of Valeant Pharmaceuticals worth $15,572,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. Signaturefd LLC lifted its position in shares of Valeant Pharmaceuticals by 78.6% during the 2nd quarter. Signaturefd LLC now owns 5,248 shares of the specialty pharmaceutical company’s stock worth $122,000 after buying an additional 2,309 shares during the last quarter. First Allied Advisory Services Inc. lifted its position in shares of Valeant Pharmaceuticals by 33.6% during the 1st quarter. First Allied Advisory Services Inc. now owns 15,101 shares of the specialty pharmaceutical company’s stock worth $242,000 after buying an additional 3,800 shares during the last quarter. Envestnet Asset Management Inc. lifted its position in shares of Valeant Pharmaceuticals by 189.4% during the 1st quarter. Envestnet Asset Management Inc. now owns 5,991 shares of the specialty pharmaceutical company’s stock worth $103,000 after buying an additional 3,921 shares during the last quarter. Gabelli Funds LLC lifted its position in shares of Valeant Pharmaceuticals by 3.5% during the 1st quarter. Gabelli Funds LLC now owns 117,088 shares of the specialty pharmaceutical company’s stock worth $1,864,000 after buying an additional 4,000 shares during the last quarter. Finally, Bedel Financial Consulting Inc. bought a new position in Valeant Pharmaceuticals in the second quarter valued at about $116,000. Institutional investors and hedge funds own 46.95% of the company’s stock.

Shares of VRX opened at $23.40 on Friday. Valeant Pharmaceuticals has a 1 year low of $10.94 and a 1 year high of $27.79. The company has a quick ratio of 0.92, a current ratio of 1.18 and a debt-to-equity ratio of 5.59. The stock has a market cap of $8.16 billion, a PE ratio of 6.11, a P/E/G ratio of 0.35 and a beta of -0.38.

Several equities analysts have commented on the company. TD Securities downgraded Valeant Pharmaceuticals from a “buy” rating to a “hold” rating and set a $24.00 target price for the company. in a research report on Friday, June 22nd. HC Wainwright reiterated a “hold” rating and issued a $20.00 target price on shares of Valeant Pharmaceuticals in a research report on Wednesday, June 20th. Barclays upgraded Valeant Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $20.00 to $34.00 in a research report on Wednesday, June 6th. Mizuho reiterated a “buy” rating and issued a $31.00 target price on shares of Valeant Pharmaceuticals in a research report on Friday, June 29th. Finally, Deutsche Bank reiterated a “buy” rating on shares of Valeant Pharmaceuticals in a research report on Friday, June 29th. Four equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Valeant Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $20.51.

Valeant Pharmaceuticals Profile

Valeant Pharmaceuticals International, Inc operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S.

Further Reading: Marijuana Stocks Investing Considerations

Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals (NYSE:VRX) (TSE:VRX).

Institutional Ownership by Quarter for Valeant Pharmaceuticals (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply